NASDAQ:DRNA - Dicerna Pharmaceuticals Stock Price, Price Target & More

Dicerna Pharmaceuticals trades on the NASDAQ under the ticker symbol "DRNA."

Dicerna Pharmaceuticals (NASDAQ:DRNA) released its earnings results on Monday, May, 14th. The biopharmaceutical company reported ($0.30) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.87) by $0.57. The biopharmaceutical company had revenue of $1.55 million for the quarter, compared to analysts' expectations of $1.75 million. Dicerna Pharmaceuticals had a negative return on equity of 123.72% and a negative net margin of 1,665.11%. View Dicerna Pharmaceuticals' Earnings History.

Dicerna Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, August, 8th 2018. View Earnings Estimates for Dicerna Pharmaceuticals.

7 analysts have issued twelve-month price targets for Dicerna Pharmaceuticals' stock. Their predictions range from $10.00 to $17.00. On average, they expect Dicerna Pharmaceuticals' stock price to reach $14.20 in the next twelve months. View Analyst Ratings for Dicerna Pharmaceuticals.

Some companies that are related to Dicerna Pharmaceuticals include Ascendis Pharma (ASND), Ironwood Pharmaceuticals (IRWD), Portola Pharmaceuticals (PTLA), Clovis Oncology (CLVS), Tesaro (TSRO), Emergent BioSolutions (EBS), Horizon Pharma (HZNP), Global Blood Therapeutics (GBT), The Medicines (MDCO), Heron Therapeutics (HRTX), ACADIA Pharmaceuticals (ACAD), Arena Pharmaceuticals (ARNA), OPKO Health (OPK), Evotec A.G. (EVTCY) and Insmed (INSM).

Media coverage about DRNA stock has been trending somewhat positive this week, Accern Sentiment reports. The research firm scores the sentiment of press coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Dicerna Pharmaceuticals earned a media sentiment score of 0.17 on Accern's scale. They also assigned headlines about the biopharmaceutical company an impact score of 48.04 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the next several days.

Dicerna Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include UBS Group AG (1.16%), Artal Group S.A. (0.82%), Millennium Management LLC (0.79%), BlackRock Inc. (0.54%), Citadel Advisors LLC (0.33%) and Spark Investment Management LLC (0.28%). Company insiders that own Dicerna Pharmaceuticals stock include Bain Capital Life Sciences Inv, Dennis Langer, Douglas Fambrough and James B Weissman. View Institutional Ownership Trends for Dicerna Pharmaceuticals.

DRNA stock was sold by a variety of institutional investors in the last quarter, including UBS Group AG. View Insider Buying and Selling for Dicerna Pharmaceuticals.

DRNA stock was acquired by a variety of institutional investors in the last quarter, including Artal Group S.A., Millennium Management LLC, Citadel Advisors LLC, BlackRock Inc., Spark Investment Management LLC, JPMorgan Chase & Co., Element Capital Management LLC and Tibra Equities Europe Ltd. Company insiders that have bought Dicerna Pharmaceuticals stock in the last two years include Bain Capital Life Sciences Inv and Douglas Fambrough. View Insider Buying and Selling for Dicerna Pharmaceuticals.

Shares of DRNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of DRNA stock can currently be purchased for approximately $13.93.

Dicerna Pharmaceuticals has a market capitalization of $726.30 million and generates $2.28 million in revenue each year. The biopharmaceutical company earns $-60,040,000.00 in net income (profit) each year or ($3.66) on an earnings per share basis. Dicerna Pharmaceuticals employs 44 workers across the globe.

Dicerna Pharmaceuticals' mailing address is 87 CAMBRIDGEPARK DRIVE, CAMBRIDGE MA, 02140. The biopharmaceutical company can be reached via phone at 617-621-8097 or via email at [email protected]